Praxis partners with Remagine Labs to develop transdermal patch for ulixacaltamide

Filed July 7, 2026 · Period ending July 7, 2026 · ~1 min read

Key Changes

• high

  Praxis entered a research collaboration with Remagine Labs to develop an iontophoretic transdermal patch for ulixacaltamide in essential tremor, complementing its existing oral formulation program.

  Item 8.01 — Other Events verify on EDGAR →
• high

  The transdermal delivery system aims to broaden the addressable patient population and strengthen ulixacaltamide's competitive positioning, potentially extending the franchise's commercial lifecycle.

  Item 8.01 — Other Events verify on EDGAR →
• medium

  Praxis made an undisclosed equity investment in Remagine Labs as part of the collaboration, signaling commitment to accelerating the transdermal patch development program.

  Item 8.01 — Other Events verify on EDGAR →